Lexaria Bioscience (LEXX) Expected to Announce Earnings on Tuesday

Lexaria Bioscience (NASDAQ:LEXX) is expected to be issuing its results before the market opens on Tuesday, November 25th. Analysts expect the company to announce earnings of ($0.16) per share and revenue of $0.1370 million for the quarter.

Lexaria Bioscience Price Performance

Lexaria Bioscience stock opened at $1.01 on Tuesday. Lexaria Bioscience has a fifty-two week low of $0.77 and a fifty-two week high of $2.85. The firm has a fifty day moving average price of $1.04 and a two-hundred day moving average price of $0.98. The firm has a market cap of $22.45 million, a price-to-earnings ratio of -1.51 and a beta of 0.71.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on LEXX. HC Wainwright decreased their target price on Lexaria Bioscience from $5.00 to $4.00 and set a “buy” rating for the company in a research note on Tuesday, July 29th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lexaria Bioscience in a report on Friday, October 31st. Finally, Wall Street Zen raised Lexaria Bioscience to a “sell” rating in a research report on Saturday, October 11th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $4.00.

Institutional Trading of Lexaria Bioscience

An institutional investor recently bought a new position in Lexaria Bioscience stock. Virtu Financial LLC acquired a new stake in Lexaria Bioscience Corp. (NASDAQ:LEXX) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 29,360 shares of the company’s stock, valued at approximately $28,000. Virtu Financial LLC owned approximately 0.13% of Lexaria Bioscience as of its most recent filing with the SEC. Institutional investors and hedge funds own 13.06% of the company’s stock.

Lexaria Bioscience Company Profile

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods.